SKYE Share Price Performance
US$1.09
-2.19 (-66.77%)
Price US$1.09
Share Pricen/a
Skye Bioscience, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
SKYE Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Skye Bioscience, Inc. Key Details
About SKYE
- Founded
- n/a
- Employees
- 16
- CEO
- WebsiteView website
Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
